Asset
ERENAPURSTAT
OPUS GENETICS INC. COMMON STOCK
Revenue
No revenue reported in loaded filings.
Clinical trials (1)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04692688 | phase2 | completed | 2021-04-08 | 2023-01-25 | Opus Genetics, Inc | Study of the Safety and Efficacy of APX3330 in Diabetic Retinopathy |
FDA applications (0)
This company has no applications containing this asset.